For research use only. Not for therapeutic Use.
Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer[1].
| Catalog Number | I022737 |
| CAS Number | 1983984-01-5 |
| Synonyms | 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol;trihydrochloride |
| Molecular Formula | C13H14Cl3N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C13H11N7O.3ClH/c14-12-16-5-3-8(19-12)7-1-2-10(21)11(18-7)9-4-6-17-13(15)20-9;;;/h1-6,21H,(H2,14,16,19)(H2,15,17,20);3*1H |
| InChIKey | YUNYDIDVURXULR-UHFFFAOYSA-N |
| SMILES | C1=CC(=NC(=C1O)C2=NC(=NC=C2)N)C3=NC(=NC=C3)N.Cl.Cl.Cl |
| Reference | [1]. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232. |
